NCT07790913
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from St. Jude Children's Research Hospital
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 2026 to Dec 2026
Notable Enrollment increased: 45 → 100 participants Show 8 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 6 words
- Start date: Sep 2026 to Oct 2026
- Interventions: Health Behavior and Lifestyle Counseling (Behavioral), Phentermine/Topiramate ER (Drug) to Health Behavior and Lifestyle Counseling (Behavioral), Phentermine/Topiramate ER (Drug)
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised
- Study description expanded, about 3 words
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Determine feasibility of obesity treatment with phentermine/topiramate ER plus health behavior and lifestyle counseling (PHEN/TOP) versus lifestyle counseling alone (SOC) in adolescents and young adults with ALL or lymphoma.
Timeframe: Baseline and Week 24
Determine the feasibility of completing obesity treatment with phentermine/topiramate ER plus health behavior and lifestyle counseling (PHEN/TOP) versus lifestyle counseling alone as standard care in adolescents and young adults with ALL or lymphoma.
Timeframe: Baseline and Week 24
Secondary (2)
Determine the tolerability of PHEN/TOP compared to SOC alone in adolescent and young adult patients with ALL or lymphoma and obesity.
Estimate preliminary efficacy of PHEN/TOP compared to SOC for change in body mass index (BMI) in adolescent and young adult patients with ALL or lymphoma and obesity.
Arms and interventions
phentermine topiramate extended release (PHEN/TOP) + Health Behavior and Lifestyle CounselingExperimental
Participants receive phentermine-topiramate extended-release orally once daily for 24 weeks using dose escalation consistent with FDA-approved obesity treatment guidelines, plus health behavior and lifestyle counseling every 4 weeks.
Health Behavior and Lifestyle Counseling Alone (SOC [Standard of Care])Active comparator
Participants receive standard health behavior and lifestyle counseling every 4 weeks for 24 weeks.
Drugs: Phentermine/Topiramate ER
Behavioral: Health Behavior and Lifestyle Counseling
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States